Authors
Latest:
Accelerating Clinical Trials With Proper Assay Development and ValidationIn this video, Dr Loren Blake (Study Director, FSP Solutions) and Jack Bradley (Executive Director) from LabConnect share their keen insights on the challenges that sponsors currently face in clinical trials, as well as ways to overcome them to accelerate outcomes.
Latest:
Immunotherapy. It’s Working.With the initial promise of immunotherapy use in oncology, we need to continue supporting cross-industry collaborations among leaders from the biopharma community, academia, regulators, and private sector investors.
Latest:
Impact of Actigraphy in Clinical ResearchWith all the buzz around wearables, actigraphs-which monitor sleep and daytime activity levels-have been around for decades.
Latest:
Data Privacy Concerns Between EU-US IntensifiesReactive, hastily enforced regulations can easily jeopardize the sound conduct of a clinical trial and its data flow, potentially threatening both subject safety and data quality.
Latest:
Building Blocks for Better BalanceWhile block randomization has been shown to be a more frequently used form of trial randomization design, the use of dynamic randomization has been shown to have optimal treatment group balancing results.
Latest:
An Adaptive-Block Randomization Method when Stratifying by Investigator in Small-to Medium-Sized StudiesA novel adaptive-block method of randomization to maximize the efficiency of overall treatment group balance, while maintaining balance at investigational centers in smaller sized studies, is proposed.
Latest:
A Comparison of Techniques for Creating Permuted Blocked Randomization ListsTwo of the most important elements to the integrity of a controlled clinical trial are the patient randomization and the treatment blinding. With a focus on block pattern distribution, four methods of randomization list creation are analyzed.
Latest:
The Benefits of Advanced Imaging Management SystemsHow new technology can impact cardiac imaging in oncology clinical trials and have broader implications for patient safety.
Latest:
Enhanced Site Training, Resources, and CommunicationSurvey drills down on the preferences and experiences of clinical trial site personnel in critical function areas such as site initiation and monitoring, training, sponsor interaction, and patient recruitment and retention.
Latest:
Enhanced Site Training, Resources, and CommunicationSurvey drills down on the preferences and experiences of clinical trial site personnel in critical function areas such as site initiation and monitoring, training, sponsor interaction, and patient recruitment and retention.
Latest:
Enhanced Site Training, Resources, and CommunicationSurvey drills down on the preferences and experiences of clinical trial site personnel in critical function areas such as site initiation and monitoring, training, sponsor interaction, and patient recruitment and retention.
Latest:
Enhanced Site Training, Resources, and CommunicationSurvey drills down on the preferences and experiences of clinical trial site personnel in critical function areas such as site initiation and monitoring, training, sponsor interaction, and patient recruitment and retention.
Latest:
How Voice Recognition Technologies Can Be Used to Accelerate Patient TrialsBecause of the growing rate of voice assistant applications, such as Alexa, healthcare and life sciences organizations are beginning to design a range of scenarios for deploying these voice assistant platforms in the clinical trial setting.
Latest:
The Hidden Costs of Paper-Based Clinical Outcome AssessmentsClinical trials using electronic Clinical Outcome Assessments (eCOA) benefit from compliance rates 300% higher than paper-based studies - but some sponsor shy away from eCOA adoption due to a misconception that paper diaries are cheaper. Read our eBook to understand the frequently neglected cost calculations proving that eCOA is the cost-effective and superior data collection solution for many clinical trials.
Latest:
Operational Challenges for Biosimilar StudiesUsing strategic planning to address hurdles in biosimilar development programs from the outset.
Latest:
Operational Challenges for Biosimilar StudiesUsing strategic planning to address hurdles in biosimilar development programs from the outset.
Latest:
Recruiting Diabetes SubjectsThe disconnect coordinating and connecting interested patients to clinical trials is an ongoing struggle.
Latest:
The 3 Essential Factors Affecting FDA Inspection OutcomeThis article focuses on the 3 essential factors that have a significant impact on the outcome of any inspection or audit. The author applies this primarily to GCP (Good Clinical Practice) inspections, but the principles are universal, being applicable to any government inspection such as the FDA (U.S. Food & Drug Administration) or industry QA (Quality Assurance) audit.
Latest:
eCOA Increases Patient-Site Communication and CandorWorldwide Clinical Trials recently announced the results of a survey that evaluated the perceptions of clinical trial site investigators who use electronic clinical outcome assessment (eCOA) technologies.
Latest:
5 Common Mistakes With Spirometry in Clinical TrialsSolutions to overcoming the most frequent missteps when collecting valuable spirometry data in respiratory studies.
Latest:
5 Common Mistakes With Spirometry in Clinical TrialsSolutions to overcoming the most frequent missteps when collecting valuable spirometry data in respiratory studies.
Latest:
5 Common Mistakes With Spirometry in Clinical TrialsSolutions to overcoming the most frequent missteps when collecting valuable spirometry data in respiratory studies.
Latest:
5 Common Mistakes With Spirometry in Clinical TrialsSolutions to overcoming the most frequent missteps when collecting valuable spirometry data in respiratory studies.
Latest:
Personalized Medicine DevelopmentAs the popularity of personalized medicine grows the role of the CRO continues to evolve.
Latest:
Set the Course for a More Engaging & Productive Patient & Clinical Trial Site JourneyDiscover how evolving clinical trial trends are reshaping patient and site experiences—and the steps sponsors can take to stay ahead—in this conversation with uMotif CEO Steve Rosenberg at SCOPE Summit 2025.
Latest:
Learning from Failure, Leveraging Biosimulation for Pediatric Drug Development SuccessPediatric trials now feature increased modeling and analytics for safer drug dosing and response.
Latest:
Learning from Failure, Leveraging Biosimulation for Pediatric Drug Development SuccessPediatric trials now feature increased modeling and analytics for safer drug dosing and response.
